Evotec AG today announced that CHDI Foundation, Inc., a privately-funded not-for-profit research organisation dedicated to developing therapies for Huntington’s disease, has extended its collaboration with Evotec until the end of 2015. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-extends-ongoing-collaboration-with-chdi-foundation-5089
Shifted Milestone Income Leads to Reduction in Operating Income Guidance for the Fiscal Year 2012
Evotec AG today announced that it is adjusting its guidance regarding profitability on operating income for the fiscal year 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/shifted-milestone-income-leads-to-reduction-in-operating-income-guidance-for-the-fiscal-year-2012-5603
Evotec receives Milestone in Drug Discovery Collaboration
Evotec AG today announced that it has received a pre-clinical milestone from its Drug Discovery Collaboration with Novartis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-milestone-in-drug-discovery-collaboration-5085
Evotec and Bayer enter into multi-target alliance to fight endometriosis
Evotec AG that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-and-bayer-enter-into-multi-target-alliance-to-fight-endometriosis-5602
Multi-target alliance with Bayer
Evotec AG today announced that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/multi-target-alliance-with-bayer-5081
Evotec and Aspireo enter into strategic advisory agreement
Evotec AG and Aspireo Pharmaceuticals Limited an Israeli biopharmaceutical company focused on the development of a novel somatostatin analogue, announced today that they have entered into a strategic advisory agreement for support in the development and partnering of Aspireo’s Somatoprim. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-aspireo-enter-into-strategic-advisory-agreement-5079
NIH awards major contract to Evotec to Manage and Operate a Small Molecule Repository
Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the National Institutes of Health, Department of Health and Human Services, for the operation of a Small Molecule Repository. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/nih-awards-major-contract-to-evotec-to-manage-and-operate-a-small-molecule-repository-5075
Building innovation on the back of profitable growth
Evotec AG today reported financial results and corporate updates for the second quarter and first half of 2012 ending 30 June 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/building-innovation-on-the-back-of-profitable-growth-5073
CureBeta, a collaboration between Evotec AG and Harvard University enters strategic alliance with Janssen Pharmaceuticals
Evotec AG today announced that it has entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc. with a particular focus on the regeneration of insulin- producing beta cells. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/curebeta-a-collaboration-between-evotec-ag-and-harvard-university-enters-strategic-alliance-with-janssen-pharmaceuticals-5600
CureBeta, a collaboration between Evotec and Harvard University enters strategic alliance with Janssen Pharmaceuticals
Evotec AG today announced that it has licensed to Janssen Pharmaceuticals, Inc. a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/curebeta-a-collaboration-between-evotec-and-harvard-university-enters-strategic-alliance-with-janssen-pharmaceuticals-5067